Alvotech will announce H1 2025 financial results on August 13, followed by a conference call on August 14.
Quiver AI Summary
Alvotech, a biotech company focused on developing biosimilar medicines, announced that it will release its financial results for the first half of 2025 on August 13, following the close of U.S. markets. A conference call to discuss these results and recent business updates will take place the next day, August 14, at 8:00 am EDT, with live audio available on Alvotech’s investor portal. The company currently markets two biosimilars, with a pipeline of nine additional candidates aimed at various health conditions. Alvotech is committed to being a leader in the biosimilar sector and has established strategic partnerships across multiple global markets to enhance its reach and expertise. Further information, including access to the conference call and webcast, can be found on their investor portal.
Potential Positives
- Alvotech plans to release financial results for the first half of 2025, indicating transparency and commitment to shareholder communication.
- The upcoming conference call presents an opportunity for investors to gain insights into the company's performance and business strategy.
- Alvotech has two approved biosimilars already marketed, showcasing its successful product development and market presence.
- The company has a diverse development pipeline with nine biosimilar candidates targeting various medical conditions, which may enhance future revenue potential.
Potential Negatives
- The press release does not provide any specific financial guidance or expectations for the upcoming earnings report, which could lead to uncertainty among investors regarding the company's financial performance.
- The absence of detailed updates on the company's development pipeline and any milestones may raise concerns about progress and competitiveness in the biosimilar market.
- Alvotech’s partnerships are extensive, but the release does not clarify the success or challenges faced in these collaborations, leaving stakeholders without insight into operational effectiveness.
FAQ
When will Alvotech release its financial results for the first half of 2025?
Alvotech will release its financial results after U.S. markets close on August 13, 2025.
How can I access the Alvotech conference call?
The conference call can be accessed via Alvotech's investor portal on August 14, 2025, at 8:00 am EDT.
Where can I find the webcast link for the earnings call?
The webcast link and access instructions can be found at https://investors.alvotech.com/events/event-details/q2-2025-earnings.
What biosimilars has Alvotech developed?
Alvotech has developed biosimilars for Humira® and Stelara®, approved in multiple global markets.
How long will the earnings call webcast be available for replay?
The webcast will be archived and available for replay for 90 days after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 26 institutional investors add shares of $ALVO stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,401,421 shares (+inf%) to their portfolio in Q1 2025, for an estimated $13,551,741
- VANGUARD GROUP INC added 995,538 shares (+31.1%) to their portfolio in Q1 2025, for an estimated $9,626,852
- SCULPTOR CAPITAL LP removed 565,359 shares (-93.3%) from their portfolio in Q1 2025, for an estimated $5,467,021
- MORGAN STANLEY removed 469,680 shares (-31.7%) from their portfolio in Q1 2025, for an estimated $4,541,805
- POINTSTATE CAPITAL LP removed 67,040 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $648,276
- OAKTREE CAPITAL MANAGEMENT LP removed 57,222 shares (-3.0%) from their portfolio in Q1 2025, for an estimated $553,336
- LODBROK CAPITAL LLP removed 25,087 shares (-13.8%) from their portfolio in Q1 2025, for an estimated $242,591
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
Full Release
REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech’s investor portal.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor portal https://investors.alvotech.com . Specifically, links to access the webcast and instructions to sign in by phone can be found at https://investors.alvotech.com/events/event-details/q2-2025-earnings . The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
